TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03903640

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Cause of deathSlow enrollment, also staffing, sites or logistics Automatic label, confidence 0.5, unverified. How labels are made.
“The study was terminated early on 03/09/2022 due to low accrual during the COVID-19 pandemic.”

The sponsor’s own words in the registry.

Life of this trial

20192020202120222023Registered2019-04-03Started2019-10-14Primary completion2020-06-08Stopped2021-11-03Results posted2022-05-12

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Washington University School of Medicine
Sponsor type
University, hospital or other
Conditions
Melanoma With Brain Metastasis
Interventions
Optune; Nivolumab; Ipilimumab
Participants
2
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.